Others Antibody

Senlizumab is a human monoclonal antibody expressed in CHO cells that specifically targets TNFSF2 (Tumor Necrosis Factor-alpha, TNF-α) . It features a huIgG4SP heavy chain and a huκ light chain, with a predicted molecular weight of 146.9 kDa. Senlizumab neutralizes the biological activity of TNF-α by blocking its interaction with TNF receptors, thereby inhibiting downstream pro-inflammatory signaling pathways. It serves as a valuable tool for research into autoimmune and inflammatory diseases. The recommended isotype control is Human IgG4 kappa, Isotype Control (HY-P99003) .